$AMED
AMEDISYS INC

2017 Q3 Form 10-Q Financial Statement

#000119312517336507 Filed on November 08, 2017

View on sec.gov

Income Statement

Concept 2017 Q3 2016 Q3
Revenue $373.7M $361.6M
YoY Change 3.35% 10.75%
Cost Of Revenue $227.3M $212.1M
YoY Change 7.15% 13.56%
Gross Profit $146.4M $149.5M
YoY Change -2.07% 7.02%
Gross Profit Margin 39.18% 41.34%
Selling, General & Admin $118.9M $129.9M
YoY Change -8.47% 11.79%
% of Gross Profit 81.22% 86.89%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $4.100M $5.300M
YoY Change -22.64% 15.22%
% of Gross Profit 2.8% 3.55%
Operating Expenses $123.0M $135.1M
YoY Change -8.96% 11.84%
Operating Profit $23.37M $14.36M
YoY Change 62.78% -14.1%
Interest Expense $1.335M $2.100M
YoY Change -36.43% -57.46%
% of Operating Profit 5.71% 14.62%
Other Income/Expense, Net $652.0K $3.835M
YoY Change -83.0% -328.96%
Pretax Income $24.03M $18.19M
YoY Change 32.05% 20.97%
Income Tax $9.364M $6.693M
% Of Pretax Income 38.98% 36.79%
Net Earnings $14.60M $11.40M
YoY Change 28.07% 35.71%
Net Earnings / Revenue 3.91% 3.15%
Basic Earnings Per Share $0.43 $0.34
Diluted Earnings Per Share $0.42 $0.34
COMMON SHARES
Basic Shares Outstanding 33.84M shares 33.31M shares
Diluted Shares Outstanding 34.36M shares 33.82M shares

Balance Sheet

Concept 2017 Q3 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $66.10M $8.900M
YoY Change 642.7% -84.41%
Cash & Equivalents $66.11M $8.915M
Short-Term Investments
Other Short-Term Assets $24.70M $22.00M
YoY Change 12.27% 290.0%
Inventory
Prepaid Expenses
Receivables $177.4M $162.5M
Other Receivables $0.00 $0.00
Total Short-Term Assets $268.2M $193.4M
YoY Change 38.68% -10.65%
LONG-TERM ASSETS
Property, Plant & Equipment $32.70M $43.00M
YoY Change -23.95% 3.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $140.1M $153.5M
YoY Change -8.73% -6.57%
Total Long-Term Assets $531.3M $528.3M
YoY Change 0.57% 17.41%
TOTAL ASSETS
Total Short-Term Assets $268.2M $193.4M
Total Long-Term Assets $531.3M $528.3M
Total Assets $799.5M $721.7M
YoY Change 10.78% 8.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $22.82M $33.10M
YoY Change -31.07% 36.63%
Accrued Expenses $83.52M $143.9M
YoY Change -41.96% 107.98%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $9.400M $5.200M
YoY Change 80.77% 36.84%
Total Short-Term Liabilities $201.9M $182.2M
YoY Change 10.81% 6.42%
LONG-TERM LIABILITIES
Long-Term Debt $80.50M $88.90M
YoY Change -9.45% -7.68%
Other Long-Term Liabilities $3.900M $4.300M
YoY Change -9.3% -13.97%
Total Long-Term Liabilities $80.50M $88.90M
YoY Change -9.45% -12.24%
TOTAL LIABILITIES
Total Short-Term Liabilities $201.9M $182.2M
Total Long-Term Liabilities $80.50M $88.90M
Total Liabilities $286.3M $276.3M
YoY Change 3.62% 1.41%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $561.4M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $53.23M
YoY Change
Treasury Stock Shares
Shareholders Equity $512.3M $445.4M
YoY Change
Total Liabilities & Shareholders Equity $799.5M $721.7M
YoY Change 10.78% 8.29%

Cashflow Statement

Concept 2017 Q3 2016 Q3
OPERATING ACTIVITIES
Net Income $14.60M $11.40M
YoY Change 28.07% 35.71%
Depreciation, Depletion And Amortization $4.100M $5.300M
YoY Change -22.64% 15.22%
Cash From Operating Activities $10.20M $6.800M
YoY Change 50.0% -77.85%
INVESTING ACTIVITIES
Capital Expenditures -$1.700M -$3.600M
YoY Change -52.78% 176.92%
Acquisitions
YoY Change
Other Investing Activities $200.0K -$4.100M
YoY Change -104.88% -38.81%
Cash From Investing Activities -$1.500M -$7.600M
YoY Change -80.26% -6.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.800M -200.0K
YoY Change 800.0% -118.18%
NET CHANGE
Cash From Operating Activities 10.20M 6.800M
Cash From Investing Activities -1.500M -7.600M
Cash From Financing Activities -1.800M -200.0K
Net Change In Cash 6.900M -1.000M
YoY Change -790.0% -104.22%
FREE CASH FLOW
Cash From Operating Activities $10.20M $6.800M
Capital Expenditures -$1.700M -$3.600M
Free Cash Flow $11.90M $10.40M
YoY Change 14.42% -67.5%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
amed Sale Of Noncontrolling Interest
SaleOfNoncontrollingInterest
0
amed Sale Of Noncontrolling Interest
SaleOfNoncontrollingInterest
405000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3282000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9074000
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
0
us-gaap Interest Paid
InterestPaid
2188000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
315000
CY2017Q3 us-gaap Liabilities
Liabilities
286310000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
11909000
CY2017Q3 us-gaap Costs And Expenses
CostsAndExpenses
356790000
CY2016Q3 us-gaap Costs And Expenses
CostsAndExpenses
347236000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
758000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
7308000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-9100000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13502000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
555000
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
4656000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
28924000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
12202000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5430000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
22584000
us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
622000
us-gaap Interest Paid
InterestPaid
2276000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
18689000
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
0
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-556000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
230000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-870000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1818000
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
1913000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
46107000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
27502000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
13664000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
14359000
CY2017Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
561380000
CY2017Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
22815000
CY2016Q4 us-gaap Minority Interest
MinorityInterest
939000
CY2017Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
86139000
CY2017Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
9387000
CY2017Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
513219000
CY2017Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
83516000
CY2017Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
799529000
CY2017Q3 us-gaap Treasury Stock Value
TreasuryStockValue
53228000
CY2017Q3 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-30545000
CY2017Q3 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
36000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
537472000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
460203000
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
512256000
CY2017Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
15000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
734029000
CY2016Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
461142000
CY2017Q3 us-gaap Minority Interest
MinorityInterest
963000
us-gaap Costs And Expenses
CostsAndExpenses
1080664000
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.43
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9364000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.02
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
3149000
CY2017Q3 amed Accrued Charge Related To Securities Class Action Lawsuit Settlement
AccruedChargeRelatedToSecuritiesClassActionLawsuitSettlement
0
CY2016Q4 amed Accrued Charge Related To Securities Class Action Lawsuit Settlement
AccruedChargeRelatedToSecuritiesClassActionLawsuitSettlement
0
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
23373000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
14558000
us-gaap Interest Expense
InterestExpense
3551000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
3602000
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.42
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3202000
us-gaap Profit Loss
ProfitLoss
34389000
CY2017Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
44000
CY2016Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
66000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
315000
us-gaap Net Income Loss
NetIncomeLoss
28344000
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1713000
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
652000
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3835000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2935000
CY2016Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6693000
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
24025000
CY2016Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
18194000
CY2016Q3 us-gaap Profit Loss
ProfitLoss
11501000
us-gaap Profit Loss
ProfitLoss
28659000
CY2017Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
103000
us-gaap Net Income Loss
NetIncomeLoss
34149000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.86
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.34
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.84
CY2017Q3 amed Securities Class Action Lawsuit Settlement
SecuritiesClassActionLawsuitSettlement
0
CY2016Q3 amed Securities Class Action Lawsuit Settlement
SecuritiesClassActionLawsuitSettlement
0
amed Securities Class Action Lawsuit Settlement
SecuritiesClassActionLawsuitSettlement
28712000
amed Securities Class Action Lawsuit Settlement
SecuritiesClassActionLawsuitSettlement
0
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
51713000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
46982000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
22000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
17228000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5896000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1798000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-150000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-18587000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4214000
us-gaap Pension Expense
PensionExpense
5134000
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34363000 shares
CY2016Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33309000 shares
amed Hospice Medicare Revenue Rate Accounted For Routine Care
HospiceMedicareRevenueRateAccountedForRoutineCare
0.98 pure
CY2016Q3 amed Revenue Adjustment To Medicare Revenue
RevenueAdjustmentToMedicareRevenue
1600000
CY2017Q3 amed Portion Of Patient Accounts Receivable Derived From Medicare
PortionOfPatientAccountsReceivableDerivedFromMedicare
0.6 pure
CY2017Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
80500000
CY2017Q3 amed General And Administrative Expense Segment
GeneralAndAdministrativeExpenseSegment
118900000
CY2016Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
2700000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
18078000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
13139000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
201000
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
0
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
128500000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14662000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
128500000
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
436000
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
750000
amed Cash Distribution To Noncontrolling Interest
CashDistributionToNoncontrollingInterest
284000
amed Cash Distribution To Noncontrolling Interest
CashDistributionToNoncontrollingInterest
216000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
0
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
35917000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
3750000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
4069000
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8915000
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
0
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
7241000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
12315000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
24128000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
amed Increase Decrease In Securities Class Action Lawsuit Settlement Accrual
IncreaseDecreaseInSecuritiesClassActionLawsuitSettlementAccrual
0
amed Increase Decrease In Securities Class Action Lawsuit Settlement Accrual
IncreaseDecreaseInSecuritiesClassActionLawsuitSettlementAccrual
0
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
6454000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
33698000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-45400000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-6885000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
73542000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-32898000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-4727000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
118000
us-gaap Use Of Estimates
UseOfEstimates
<p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Use of Estimates</font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Our accounting and </font><font style="font-family:Times New Roman;font-size:10pt;">reporting policies conform with </font><font style="font-family:Times New Roman;font-size:10pt;">U.S.</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">G</font><font style="font-family:Times New Roman;font-size:10pt;">AAP</font><font style="font-family:Times New Roman;font-size:10pt;">. </font><font style="font-family:Times New Roman;font-size:10pt;">In preparing the </font><font style="font-family:Times New Roman;font-size:10pt;">unaudited </font><font style="font-family:Times New Roman;font-size:10pt;">condensed </font><font style="font-family:Times New Roman;font-size:10pt;">consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the</font><font style="font-family:Times New Roman;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;">condensed </font><font style="font-family:Times New Roman;font-size:10pt;">consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.</font></p>
amed Episodes In Progress That Begin During Reporting Period
EpisodesInProgressThatBeginDuringReportingPeriod
60
amed Rate Of Request For Anticipated Payment Submitted For Subsequent Episodes Of Care
RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare
0.5 pure
amed Maximum Days To Submit Final Bill From Start Of Episode
MaximumDaysToSubmitFinalBillFromStartOfEpisode
120
amed Maximum Days To Submit Final Bill From Date Request For Anticipated Payment Was Paid
MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid
60
CY2017Q3 amed Revenue Adjustment To Medicare Revenue
RevenueAdjustmentToMedicareRevenue
3500000
amed Revenue Adjustment To Medicare Revenue
RevenueAdjustmentToMedicareRevenue
11900000
amed Revenue Adjustment To Medicare Revenue
RevenueAdjustmentToMedicareRevenue
5900000
us-gaap Comparability Of Prior Year Financial Data
ComparabilityOfPriorYearFinancialData
<p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;margin-left:0px;">Reclassifications and Comparability</font></p><p style='margin-top:9pt; margin-bottom:0pt'><font style="font-family:Times New Roman;font-size:10pt;margin-left:0px;">Certain reclassifications have been made to prior periods' financial statements in order to conform to the current period's presentation.</font></p><p style='margin-top:9pt; margin-bottom:0pt'>&#160;</p>
CY2017Q3 amed Minimum Percent Ownership For Controlling Interest Percent
MinimumPercentOwnershipForControllingInterestPercent
0.50 pure
CY2017Q3 us-gaap Number Of States In Which Entity Operates
NumberOfStatesInWhichEntityOperates
34 States
CY2016Q4 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
27800000
CY2017Q3 amed Maximum Percent Ownership For Cost Method Percent
MaximumPercentOwnershipForCostMethodPercent
0.20 pure
CY2017Q3 amed Maximum Percent Ownership For Equity Method Percent
MaximumPercentOwnershipForEquityMethodPercent
0.50 pure
CY2017Q3 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
26800000
amed Episode Of Care As Episodic Based Revenue
EpisodeOfCareAsEpisodicBasedRevenue
60
amed First Threshold Of Therapy Services Required
FirstThresholdOfTherapyServicesRequired
6 Number_of_Visits
amed Third Threshold Of Therapy Services Required
ThirdThresholdOfTherapyServicesRequired
20 Number_of_Visits
amed Low Utilization Payment Adjustment Number Of Visits
LowUtilizationPaymentAdjustmentNumberOfVisits
5 Number_of_Visits
CY2017Q3 amed Hospice Medicare Revenue Rate Accounted For Routine Care
HospiceMedicareRevenueRateAccountedForRoutineCare
0.98 pure
amed Hospice Medicare Revenue Rate Accounted For Routine Care
HospiceMedicareRevenueRateAccountedForRoutineCare
0.99 pure
amed Percentage Of Total Reimbursement Of Outlier Payment
PercentageOfTotalReimbursementOfOutlierPayment
0.10 pure
amed Second Threshold Of Services Required
SecondThresholdOfServicesRequired
14 Number_of_Visits
CY2016Q3 amed Hospice Medicare Revenue Rate Accounted For Routine Care
HospiceMedicareRevenueRateAccountedForRoutineCare
0.99 pure
amed Percentage Of Patient Receivables Outstanding
PercentageOfPatientReceivablesOutstanding
0.1 pure
amed Minimum Days Accounts Receivable Outstanding Fully Reserved
MinimumDaysAccountsReceivableOutstandingFullyReserved
365
CY2016 amed Portion Of Patient Accounts Receivable Derived From Medicare
PortionOfPatientAccountsReceivableDerivedFromMedicare
0.61 pure
amed Historical Collection Rate From Medicare
HistoricalCollectionRateFromMedicare
0.99 pure
amed Rate Of Request For Anticipated Payment Submitted For Initial Episode Of Care
RateOfRequestForAnticipatedPaymentSubmittedForInitialEpisodeOfCare
0.6 pure
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
279000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
254000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
279000 shares
CY2017Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
92000000
CY2017Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
337000 shares
CY2016Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
204000 shares
CY2017Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
271000 shares
CY2016Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
207000 shares
CY2017Q3 amed Non Vested Stock And Stock Units
NonVestedStockAndStockUnits
254000 shares
CY2016Q3 amed Non Vested Stock And Stock Units
NonVestedStockAndStockUnits
307000 shares
amed Non Vested Stock And Stock Units
NonVestedStockAndStockUnits
336000 shares
amed Non Vested Stock And Stock Units
NonVestedStockAndStockUnits
401000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
156000 shares
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33838000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33640000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34255000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33699000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33142000 shares
CY2016Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33823000 shares
CY2017Q3 us-gaap Long Term Debt
LongTermDebt
89900000
CY2016Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
87800000
CY2017Q3 amed Total Leverage Ratio
TotalLeverageRatio
0.9 pure
CY2017Q3 amed Fixed Charge Coverage Ratio
FixedChargeCoverageRatio
4.1 pure
CY2017Q3 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
2100000
CY2016Q4 us-gaap Long Term Debt
LongTermDebt
93000000
CY2017Q3 amed Corporate Integrity Agreement Term
CorporateIntegrityAgreementTerm
P5Y
amed Health Insurance Retention Limit
HealthInsuranceRetentionLimit
900000
amed Workers Compensation Insurance Retention Limit
WorkersCompensationInsuranceRetentionLimit
500000
amed Professional Liability Insurance Retention Limit
ProfessionalLiabilityInsuranceRetentionLimit
300000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3 Segments
amed General And Administrative Expense Segment
GeneralAndAdministrativeExpenseSegment
358500000
amed General And Administrative Expense Segment
GeneralAndAdministrativeExpenseSegment
378500000

Files In Submission

Name View Source Status
0001193125-17-336507-index-headers.html Edgar Link pending
0001193125-17-336507-index.html Edgar Link pending
0001193125-17-336507.txt Edgar Link pending
0001193125-17-336507-xbrl.zip Edgar Link pending
amed-20170930.xml Edgar Link completed
amed-20170930.xsd Edgar Link pending
amed-20170930_cal.xml Edgar Link unprocessable
amed-20170930_def.xml Edgar Link unprocessable
amed-20170930_lab.xml Edgar Link unprocessable
amed-20170930_pre.xml Edgar Link unprocessable
d471402d10q.htm Edgar Link pending
d471402dex101.htm Edgar Link pending
d471402dex102.htm Edgar Link pending
d471402dex311.htm Edgar Link pending
d471402dex312.htm Edgar Link pending
d471402dex321.htm Edgar Link pending
d471402dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g471402dsp1.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending